Alkem Labs Q4 FY26: Revenue up 14.6%, stock jumps on beat

What moved the stock

Alkem Laboratories’ shares rose about 1.3 percent to around Rs 5,452 per share on the BSE after the company announced its March-quarter (Q4 FY26) results during market hours. The move came even as reported profit fell year-on-year, with investors focusing on strong revenue growth, a sharp improvement in operating performance, and management’s commentary on the FY27 launch pipeline.

Q4 FY26 results: profit down, revenue up

For Q4 FY26, Alkem reported a sharp drop in consolidated net profit even though the top line expanded at a double-digit pace.

• Consolidated net profit fell 22.7 percent year-on-year to Rs 236 crore.
• Another report pegged Q4 consolidated net profit at Rs 251.11 crore, a 25.11 percent decline.
• Revenue from operations rose 14.6 percent to Rs 3,603 crore (also reported as Rs 3,603.32 crore).
• EBITDA for the quarter increased 32.2 percent year-on-year.

The company’s results also referenced an I/B/E/S profit estimate comparison showing Q4 net profit of 2.36 billion rupees (Rs 236 crore) versus an estimate of 4.7 billion rupees (Rs 470 crore).

Why net profit fell: exceptional items and tax impact

Management attributed the weaker reported profit to one-time exceptional items and a higher tax charge in the quarter.

The exceptional items cited included:

• Labour Code-related gratuity liabilities
• Impairment of real-estate investments
• A one-time deferred tax adjustment linked to Alkem’s transition to the new tax regime

Vikas Gupta, chief executive officer of Alkem, said the quarter saw strong operational progress when exceptional items are excluded. He noted that profit before tax before exceptional items rose 40.7 percent during the quarter, and another disclosure put profit before exceptional items and tax at Rs 557.82 crore, up 40.74 percent year-on-year.

Core operating performance: margin expansion in focus

Despite the profit decline, Alkem emphasised that the quarter reflected “very strong top-line growth” and “very strong EBITDA growth” along with margin improvement.

The operating leverage is visible in the gap between revenue growth (14.6 percent) and EBITDA growth (32.2 percent) in Q4 FY26. Management also highlighted that FY26 marked the company’s highest-ever EBITDA.

Full-year FY26: profit grows, revenue crosses Rs 14,700 crore

On an annual basis, Alkem reported steady growth.

• FY26 net profit rose 6 percent to Rs 2,301 crore.
• Another report put FY26 net profit at Rs 2,301.80 crore, up 6.3 percent versus Rs 2,165.48 crore in FY25.
• FY26 revenue from operations increased to Rs 14,712.2 crore (also reported as Rs 14,712.3 crore), up around 13 percent.
• FY26 EBITDA surpassed Rs 3,000 crore, and FY26 EBITDA was reported to be up 19.6 percent year-on-year.

Management said Alkem delivered strong business growth and operational execution across India and international markets, with chronic therapies emerging as a major growth driver.

FY27 outlook: India growth, US launch pipeline

Alkem outlined an FY27 product pipeline with emphasis on the US market.

• The company plans seven to eight launches in the US during FY27.
• Two key launches highlighted were Tolvaptan (for treating low blood sodium levels) and Lidocaine patches (a local anaesthetic medication), expected around September-October in the second half of FY27.

On business outlook:

• Alkem expects India branded formulations to continue outperforming the Indian Pharmaceutical Market (IPM) by 100-250 basis points.
• Another guidance point indicated a target to grow 100-150 basis points above the market in India.
• The US business is expected to grow in high single digits in dollar terms.

Semaglutide launch adds context to India strategy

The company has also launched a semaglutide injection in India for the diabetes and weight loss market. The product is sold under brand names including Semasize and Obesema.

Key disclosed pricing details:

• A pre-filled pen for a month’s dosage was priced at Rs 1,800.
• The implied weekly therapy cost was Rs 450.

While this launch is separate from Q4 earnings, it provides context for Alkem’s focus on chronic therapies and differentiated introductions.

Tax and regulatory backdrop: relief and demands in FY26

The company has faced a series of tax-related developments in recent months, as reflected in headlines referenced alongside the earnings update.

• May 5, 2026: Order-in-appeal dropped a tax demand of Rs 69.66 crore.
• Apr 24, 2026: Tax demand of Rs 330 crore.
• Another disclosure referenced a tax demand of Rs 3.83 crore and a tax penalty of Rs 0.38 crore.

In Q4, management also linked a one-time deferred tax adjustment to the company’s shift to the new tax regime, which contributed to the profit decline.

Dividend update

Alkem’s board recommended a final dividend of Rs 10 per equity share of face value Rs 2 for the financial year ended March 31, 2026.

Key numbers at a glance

Market impact and why the quarter matters

The stock’s rise on a day of lower reported profit suggests the market treated Q4 as a “quality of earnings” quarter, separating core operating momentum from one-off charges. Revenue growth of 14.6 percent and EBITDA growth of 32.2 percent point to stronger operating efficiency, while management’s focus on chronic therapies aligns with where prescription growth has been stronger in India.

The FY27 pipeline adds a second leg to the narrative. Guidance of high single-digit US growth in dollar terms, combined with seven to eight planned launches, puts execution and timing at the centre of investor tracking, especially for products management called out for the second half of FY27.

What to watch next

Investors are likely to track three near-term signposts: clarity on the quantum and recurrence of exceptional items, progress on the September-October window for the highlighted US launches, and follow-through on India outperformance versus the IPM in chronic therapies. Any further tax-related updates, given the recent sequence of demands and relief orders, will also remain in focus.